Danielle Barsa
University of California, Los Angeles
7 Papers
18 Citations
Danielle Barsa is an academic researcher from University of California, Los Angeles. The author has contributed to research in topics: Prostate cancer & Biopsy. The author has an hindex of 4, co-authored 7 publications.
Chat about Author
Papers
Risk of Prostate Cancer after a Negative Magnetic Resonance Imaging Guided Biopsy.
Adam Kinnaird,Vidit Sharma,Ryan Chuang,Alan Priester,Elizabeth Tran,Danielle Barsa,Merdie Delfin,Lorna Kwan,Anthony Sisk,Ely Felker,Leonard S. Marks +10 more
TL;DR: Men with a negative MRI, following an initial negative MRGB, are unlikely to harbor csPCa and may avoid repeat biopsy, however, when lesions are seen on follow-up MRI, repeat MRGB biopsy is warranted.
27
Magnetic Resonance Imaging–Guided Confirmatory Biopsy for Initiating Active Surveillance of Prostate Cancer
Rajiv Jayadevan,Ely Felker,Lorna Kwan,Danielle Barsa,Haoyue Zhang,Anthony Sisk,Merdie Delfin,Leonard S. Marks +7 more
- 04 Sep 2019
TL;DR: This cohort study examines the association of magnetic resonance imaging−guided confirmatory prostate biopsy findings with the risk of pathologic disease upgrading during active surveillance for prostate cancer.
Hemigland Cryoablation of Clinically Significant Prostate Cancer: Intermediate-Term Followup via Magnetic Resonance Imaging Guided Biopsy.
Ryan Chuang,Adam Kinnaird,Lorna Kwan,Anthony Sisk,Danielle Barsa,Ely Felker,Merdie Delfin,Leonard S. Marks +7 more
TL;DR: Hemigland cryoablation, when rigorously evaluated by all utilities of magnetic resonance imaging guided biopsy, appears to eliminate clinically significant cancer in 82% of men, a success rate that endures for at least 18 months.
20
Use of MRI-Guided Biopsy for Selection and Follow-up of Men Undergoing Hemi-gland Cryoablation of Prostate Cancer.
Steve Zhou,Demetrios N. Simopoulos,Rajiv Jayadevan,Ely Felker,Merdie Delfin,Danielle Barsa,Lorna Kwan,Leonard S. Marks +7 more
TL;DR: Hemi-gland cryoablation for clinically-significant CaP is well-tolerated, and when patients are selected and followed by MRI/US fusion biopsy, cancer control appears promising at 6 months.
8
Genetic Factors Associated with Prostate Cancer Conversion from Active Surveillance to Treatment
Yu Jiang,Travis J. Meyers,Adaeze A. Emeka,Lauren Folgosa Cooley,Phillip R. Cooper,Nicola Lancki,Irene Helenowski,Linda Kachuri,Daniel W. Lin,Daniel W. Lin,Janet L. Stanford,Janet L. Stanford,Lisa F. Newcomb,Lisa F. Newcomb,Suzanne Kolb,Suzanne Kolb,Antonio Finelli,Neil E. Fleshner,Maria Komisarenko,James A. Eastham,Behfar Ehdaie,Nicole Benfante,Christopher J. Logothetis,Justin R. Gregg,Cherie Perez,Sergio Garza,Jeri Kim,Leonard S. Marks,Merdie Delfin,Danielle Barsa,Danny Vesprini,Laurence Klotz,Andrew Loblaw,Alexandre Mamedov,S. Larry Goldenberg,Celestia S. Higano,Maria Spillane,Eugenia Wu,H. Ballentine Carter,Christian P. Pavlovich,Mufaddal Mamawala,Tricia Landis,Peter R. Carroll,June M. Chan,Matthew R. Cooperberg,Janet E. Cowan,Todd M. Morgan,Javed Siddiqui,Rabia Martin,Eric A. Klein,Karen Brittain,Paige Gotwald,DA Barocas,Jeremiah R. Dallmer,Jeremiah R. Dallmer,Jennifer B. Gordetsky,Pam Steele,Shilajit Kundu,Jazmine Stockdale,Monique J. Roobol,Lionne D.F. Venderbos,Martin G. Sanda,Rebecca S. Arnold,Dattatraya Patil,Christopher P. Evans,Marc A. Dall'Era,Anjali Vij,Anthony J. Costello,Ken Chow,Niall M. Corcoran,Soroush Rais-Bahrami,Courtney Phares,Douglas S. Scherr,Thomas Flynn,R. Jeffrey Karnes,Michael O. Koch,Courtney Rose Dhondt,Joel B. Nelson,Dawn McBride,Michael S. Cookson,Kelly L. Stratton,Stephen Farriester,Erin Hemken,Walter M. Stadler,Tuula Pera,Deimante Banionyte,Fernando J. Bianco,Isabel H. Lopez,Stacy Loeb,Samir S. Taneja,Nataliya Byrne,Christopher L. Amling,Ann Martinez,Luc Boileau,Franklin Gaylis,Jacqueline Petkewicz,Nicholas Kirwen,Brian T. Helfand,Jianfeng Xu,Denise M. Scholtens,William J. Catalona,John S. Witte +101 more
TL;DR: In this article, a multi-institutional genome-wide association study (GWAS) of 6,361 PC patients who initially elected active surveillance and were followed over time for the potential outcome of conversion from AS to active treatment was conducted.
7